Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen
NCT04940065 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 367
Last updated 2025-11-28
Summary
This study was an uncontrolled, central registration system, open-label, multicenter observational study in patients using Kesimpta for the labeled indication.
Conditions
- Relapsing-remitting Multiple Sclerosis
- Active Secondary Progressive Multiple Sclerosis
Interventions
- OTHER
-
Kesimpta
Prospective observational cohort study. There was no treatment allocation.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Eligibility
- Min Age
- 0 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-06-30
- Primary Completion
- 2024-12-12
- Completion
- 2024-12-12
Countries
- Japan
Study Locations
More Related Trials
-
Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"
NCT03209479 ·Status: COMPLETED
-
Characterizing the Use of Ofatumumab in a Real World Setting
NCT05090033 ·Status: COMPLETED
-
Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies
NCT05566756 ·Status: COMPLETED
-
COMparison Between All immunoTherapies for Multiple Sclerosis.
NCT03193866 ·Status: COMPLETED
-
Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)
NCT00537082 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China
NCT05199571 ·Status: COMPLETED ·Phase: PHASE4
-
ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients
NCT06345157 ·Status: ACTIVE_NOT_RECRUITING
-
Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation
NCT06668324 ·Status: COMPLETED
-
The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis
NCT06599307 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT05551598 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05147220 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis
NCT05496894 ·Status: WITHDRAWN ·Phase: PHASE2
-
Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).
NCT04260711 ·Status: UNKNOWN ·Phase: NA
-
A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data
NCT06854341 ·Status: COMPLETED
-
Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis
NCT00219908 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis
NCT02583594 ·Status: COMPLETED ·Phase: PHASE1
-
A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
NCT01808482 ·Status: TERMINATED ·Phase: PHASE1
-
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients
NCT04593927 ·Status: COMPLETED
-
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
NCT05925049 ·Status: ACTIVE_NOT_RECRUITING
-
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)
NCT01405820 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis
NCT00333138 ·Status: COMPLETED ·Phase: PHASE2
-
The Multicenter, Open-label, Single-use Autoinjector Convenience Study
NCT00958009 ·Status: COMPLETED ·Phase: PHASE3
-
Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)
NCT04121065 ·Status: RECRUITING
-
Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)
NCT03653273 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3